Doxazosin

Cardura IR treats BPH signs/symptoms and hypertension and can be used alone or with other antihypertensives. Cardura XL treats BPH signs/symptoms and explicitly is not indicated for hypertension. This profile follows those current U.S. product labels; it does not establish an off-label indication or declare alpha blockade the preferred initial hypertension treatment.

Prostate cancer can cause similar symptoms and coexist with BPH; evaluate and rule it out before BPH treatment. Doxazosin relieves the dynamic smooth-muscle component of obstruction. Improvement does not establish that prostate enlargement or another cause of obstruction has resolved.

Give once daily; individualize titration and monitor BP. The maximum depends on the indication.

Take with breakfast and swallow whole; never chew, divide, cut or crush. Empty nonabsorbable tablet shells may appear in stool. XL is not a milligram-for-milligram substitution instruction for IR.

A PDE-5 inhibitor can add symptomatic BP lowering. In patients taking Cardura XL, initiate the PDE-5 inhibitor at its lowest dose. Review BP, orthostatic symptoms and the specific PDE-5 product’s precautions; no universal safe dose separation is established here.

Do not use with hypersensitivity to doxazosin, other quinazolines such as prazosin/terazosin, or the product’s components. GI narrowing and hepatic impairment are important warnings, not additional formal contraindications invented from section 5.

Neither selected current Cardura IR nor Cardura XL label carries a boxed warning. Clinically significant first-dose hypotension/syncope still requires dose precautions and counseling.

Dizziness, fatigue/asthenia, somnolence and hypotension are important effects; headache is also common with XL. IR trials report edema and dose-related postural effects. Postmarketing reports include priapism, blood-count abnormalities, cholestatic hepatic injury and IFIS; frequency/causality cannot be reliably estimated from spontaneous reports. Overdose chiefly produces hypotension and requires urgent assessment/supportive care. High protein binding makes dialysis an ineffective removal strategy.

Review all prescription and nonprescription medicines before initiation or a dose increase.

Cardura XL has no in-vivo PK interaction trials; IR cimetidine findings cannot be transferred quantitatively to XL. Monitor the patient rather than assuming the same exposure change across release designs.

Pediatric safety/effectiveness are not established. Use cautious dose selection in older adults. XL hypotension appears more frequent at age 70 or older, and elderly exposure is higher. IR BPH studies reported generally similar safety/effectiveness between older and younger patients, but that does not remove first-dose and fall precautions.

Severe hepatic impairment is not recommended with either product. Monitor IR patients with mild/moderate impairment for hypotension; administer XL cautiously in those groups. IR PK studies did not show significant alteration with renal impairment, but assess BP and overall clinical condition. XL has different absorption kinetics; this profile does not invent an eGFR-based dose algorithm or a dedicated XL renal study.

IR may be considered for its hypertension indication only after individual assessment; limited human pregnancy data cannot establish major-malformation/miscarriage risk. Untreated maternal hypertension itself carries risk. Doxazosin has been reported in human milk, with inadequate infant-effect and milk-production information. XL is not indicated in females or for hypertension; do not transfer the IR indication to a pregnancy/XL regimen.

Alpha-1 receptor blockade relaxes prostate/bladder-neck smooth muscle and lowers urethral resistance, improving BPH symptoms/flow. IR antihypertensive effects result from reduced systemic vascular resistance; greatest BP reduction typically occurs 2–6 hours after dosing and can be greater while standing. This mechanism does not make XL an approved hypertension product.

IR peak levels usually occur around 2–3 hours, oral bioavailability is about 65%, and terminal half-life about 22 hours. XL provides controlled release over 24 hours, with typical steady-state peaks around 8–9 hours and apparent half-life 15–19 hours. Breakfast gives more consistent XL exposure. Doxazosin is about 98% protein bound and extensively hepatically metabolized, predominantly via CYP3A4 in vitro; fecal elimination predominates. Different PK precludes casual IR/XL dose equivalence.

Check seated/standing BP and symptoms, response to BPH or hypertension treatment, falls, adherence and interacting drugs. IR label requires at least six-hour BP monitoring after the initial dose and each increase. Evaluate BPH’s alternative causes/prostate cancer before treatment; reassess persistent or changing symptoms. Watch for new/worsening angina with XL, hepatic-risk tolerability and severe constipation/obstruction symptoms.

Rise carefully; if dizzy/lightheaded, sit or lie down and seek advice if symptoms persist. IR counseling advises avoiding driving/hazardous tasks for 24 hours after the first dose, an increase or resuming after interruption; XL advises avoiding hazardous tasks until effects are known. Get urgent care for fainting with injury, severe persistent abdominal pain or prolonged painful erection. Tell the eye surgeon about all past/current alpha-blocker use. XL goes with breakfast, whole; seeing its empty shell in stool can be normal. Ask before restarting after several missed days.

Cardura IR 1 mg is a white round tablet marked CN1 and VLE; selected bottle of 100 NDC 58151-074-01. Cardura XL 4 mg is white and marked CXL 4; selected bottle of 30 NDC 58151-078-93. These examples identify selected label packages and do not establish stock availability.

Cardura IR tablets: 1, 2, 4 and 8 mg doxazosin free-base equivalent as the mesylate salt. Cardura XL extended-release tablets: 4 and 8 mg. The salt amount differs from the labeled free-base equivalent; prescribe the displayed doxazosin strength and release design rather than converting mesylate mass.

Selected IR and XL labels specify storage at 25°C, with excursions 15–30°C. XL package panels additionally say protect from moisture and humidity. Keep medicine away from children. Preserve XL tablets whole; follow the exact manufacturer’s packaging and expiry instructions.